Explore every episode of the podcast Cholesterol Conversations
| Title | Pub. Date | Duration | |
|---|---|---|---|
| Mastering LDL Management in 2025 | 30 Mar 2025 | 00:29:44 | |
In this episode of Cholesterol Conversations, host Dr. Heather Johnson, Director of Preventive Cardiology for Women's Services at the Christine E. Lynn Womenās Health & Wellness Institute of Baptist Health South Florida, sits down with Dr. Viet T. Le, Associate Professor of Research and Co-Director of the Preventive Cardiology Clinic at Intermountain Medical Center in Utah. Together, they explore the latest advancements in LDL cholesterol management and discuss how clinicians can optimize risk assessment, treatment strategies, and patient adherence to improve cardiovascular outcomes. From discussing the new AHA PREVENT calculator to strategies for overcoming statin intolerance and emerging lipid-lowering therapies, this podcast provides practical insights into treating and preventing cardiovascular disease in 2025 ā in just 30 minutes! š§ Listen Now to stay ahead in lipid management and help patients achieve better heart health. This activity has been approved for AMA PRA Category 1 Credit(s)ā¢. After listening to the podcast discussion, go to Boston University Chobanian & Avedisian School of Medicineās website:Ā Cholesterol Conversations: Mastering LDL Management in 2025 | Chobanian & Avedisian School of Medicine/CCE. Scroll down for more information about CME/CPE credits. š” For more educational content on LDL cholesterol management, visit: Vasculearn Network Ā Podcast Chapters: 1. Introduction & Overview (00:06 - 01:18) 2. Why is LDL Important? (01:18 - 03:47) 3. Risk Assessment & Screening Tools (03:47 - 08:39) 4. Special Risk Considerations (08:39 - 10:55) 5. Lipoprotein(a) & Additional Biomarkers (10:55 - 12:05) 6. Treatment Options: Statins & Beyond (12:05 - 17:24) 7. Overcoming Statin Intolerance (17:24 - 21:37) 8. Barriers to Treatment & Access Issues (21:37 - 25:00) 9. Future Directions & Emerging Therapies (25:00 - 28:23) 10. Final Takeaways (28:23 - 29:44) Ā Learning Objectives At the end of this activity, the learner should be better able to:
Ā Launch Date: 3/31/2025 Expiration Date: 3/30/2026 Ā Joint Accreditation In support of improving patient care, this activity has been planned and implemented by Boston University Chobanian & Avedisian School of Medicine and Vasculearn Network. Boston University Chobanian & Avedisian School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Ā Physician CME Hours
Ā Pharmacist Contact Hours Ā Speakers Disclosures Dr. Heather Johnson, MD, MS
Ā Viet Le, DMSc, MPAS, PA-C Ā Disclosures: Dr. Le is on the advisory board for Amarin, Amgen, Bayer, Idorsia, Lexicon, Merck, Novartis and Pfizer. He also receives grant research support from Johnson & Johnson and Janssen, Kardi and AliveCor and Novartis.Ā Ā Off-Label Discussion:Ā will not be included. Ā John Fanikos, Rph, MBAĀ Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā Ā
Ā In accordance with the Standards for Integrity and Independence in Accredited Continuing Education, all relevant financial relationships that faculty, planners, authors, and anyone who may be in control of content have with ineligible companies have been mitigated. Ā How to Earn Credit and Obtain Your CertificateĀ Ā Physician CME Credits and Nursing CNE Education Credits: Ā How to Request a CME and CNE Certificate Ā After listening to the podcast discussion, the activity go to Boston University Chobanian & Avedisian School of Medicineās website: Cholesterol Conversations: Mastering LDL Management in 2025 | Chobanian & Avedisian School of Medicine/CCE. Ā To receive a certificate for your participation in this activity, you will need to create an account on the CME Office's website and complete the evaluation survey. Then your certificate will be available for immediate download. Ā Requirements for Pharmacist CE Credit Ā Instructions for Completing a Program Evaluation and Earning CPE credit
Ā Please note: ACPE will only accept CPE data that is reported by providers within 60 days of the live program or completing the home-study. CPE data is reported immediately to the CPE Monitor upon your completion of this evaluation although it may take 48-72 hours to appear in your CPE Monitor profile.Ā You will be notified of any problems transmitting your participant data via email. Most transmission problems are related to errors in transcribing date of birth and/or NABP ID number. It is strongly recommended that you check your profile in the CPE Monitor to verify your participation in this program has been reported. CPE Monitor will reject CE data submitted after 60 days. *Your pharmacy license number and date of birth in order to report participant data to the CPE Monitor.Ā Pharmacy license numbers will not be used for any other purpose. Ā For questions about ACPE accreditation, contact Boston University Chobanian & Avedisian School of Medicine Center for Continuing Education at: cme@bu.edu. Ā Commercial Support This program is supported through educational grants from Esperion Therapeutics Inc. and Merck & Co., Inc. Ā Ā | |||
| How Do We Get There from Here: Partnering with Patients to Achieve LDL Goals | 08 Mar 2023 | 00:19:16 | |
In this episode ofĀ Cholesterol Conversations, Drs. Marc Bonaca, Pam Taub, and Heather Johnson discuss how multiagent therapy can improve the provision of care in the real world. Covered topics include new data from the 2023 ACC Scientific Sessions on the efficacy of novel agents and the role of combination therapy, as well as the importance of shared decision-making and keys to managing high-risk populations. | |||
| ASCVD Management: Making the Case for Nonstatin Therapies | 21 Feb 2023 | 00:21:25 | |
In this episode of Cholesterol Conversations, join Drs. Neha Pagidipati, Christie Ballantyne, and Gregory Piazza for a roundtable discussion that addresses recent guidance on ASCVD management, current gaps in ASCVD care, patient barriers to LDL-C lowering, and nonstatin therapies to consider forĀ patients who donāt respond to statin therapy alone. | |||